Free Trial

Medtronic (MDT) Stock Forecast & Price Target

Medtronic logo
$92.62 +1.52 (+1.67%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$92.35 -0.27 (-0.29%)
As of 08/22/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
8
Buy
10

Based on 18 Wall Street analysts who have issued ratings for Medtronic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 8 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for MDT.

Consensus Price Target

$101.15
9.21% Upside
According to the 18 analysts' twelve-month price targets for Medtronic, the average price target is $101.15. The highest price target for MDT is $110.00, while the lowest price target for MDT is $95.00. The average price target represents a forecasted upside of 9.21% from the current price of $92.62.
Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medtronic and its competitors.

Sign Up

MDT Analyst Ratings Over Time

TypeCurrent Forecast
8/24/24 to 8/24/25
1 Month Ago
7/25/24 to 7/25/25
3 Months Ago
5/26/24 to 5/26/25
1 Year Ago
8/25/23 to 8/24/24
Strong Buy
1 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
Hold
8 Hold rating(s)
11 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$101.15$98.19$96.07$92.92
Forecasted Upside9.21% Upside5.68% Upside19.04% Upside5.18% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold

MDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Medtronic Stock vs. The Competition

TypeMedtronicMedical CompaniesS&P 500
Consensus Rating Score
2.61
2.79
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside9.21% Upside13,202.85% Upside9.65% Upside
News Sentiment Rating
Positive News

See Recent MDT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/21/2025Citigroup
2 of 5 stars
Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$99.00 ➝ $101.00+9.69%
8/21/2025Truist Financial
3 of 5 stars
Richard Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$92.00 ➝ $96.00+4.50%
8/20/2025UBS Group
3 of 5 stars
Danielle Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$94.00 ➝ $95.00+1.83%
8/20/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Larry Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$98.00 ➝ $100.00+7.19%
8/20/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lee Hambright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$97.00 ➝ $98.00+8.99%
8/20/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$94.00 ➝ $96.00+6.77%
8/14/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mike Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
7/16/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$98.00 ➝ $100.00+12.04%
7/15/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Cecilia Furlong
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$98.00 ➝ $107.00+20.16%
7/11/2025BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral
7/11/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Vazquez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vijay Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$103.00 ➝ $106.00+20.83%
6/30/2025Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mike Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Peer Perform
6/16/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mike Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$110.00+26.16%
5/22/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$105.00 ➝ $101.00+24.10%
11/26/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$105.00 ➝ $109.00+27.11%
11/15/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$99.00 ➝ $96.00+9.84%
8/23/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Department
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/21/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$85.00 ➝ $90.00+4.41%
8/21/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$85.00 ➝ $87.00+1.90%
8/21/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$92.00 ➝ $94.00+10.10%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell$83.00+1.84%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:12 PM ET.


Should I Buy Medtronic Stock? MDT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, August 23, 2025. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

Medtronic
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Medtronic plc:

  • The current stock price is around $92.62, which reflects a recent increase of 1.7%, indicating positive market sentiment.
  • Medtronic plc reported strong quarterly earnings, with earnings per share of $1.26, surpassing analysts' expectations, which suggests robust financial health.
  • The company has a solid revenue growth of 7.7% year-over-year, demonstrating its ability to expand and capture market share.
  • Medtronic plc has a consistent dividend payout, with a recent quarterly dividend of $0.71 per share, translating to an annualized yield of 3.1%, appealing to income-focused investors.
  • Analysts have a consensus rating of "Moderate Buy" for Medtronic plc, with a target price of $101.15, indicating potential for price appreciation.

Medtronic
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Medtronic plc for these reasons:

  • The stock has a relatively high price-to-earnings (P/E) ratio of around 25.52, which may suggest that it is overvalued compared to its earnings.
  • Medtronic plc's dividend payout ratio is currently at 78.24%, indicating that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
  • Despite recent positive earnings, the stock has experienced volatility, with a twelve-month high of $96.25 and a low of $79.29, reflecting potential risks in price stability.
  • Market analysts have mixed ratings, with some downgrading the stock from "buy" to "hold," which may indicate uncertainty about future performance.
  • The company operates in a highly competitive medical technology sector, which could impact its market position and profitability in the long term.

MDT Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Medtronic is $101.15, with a high forecast of $110.00 and a low forecast of $95.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 8 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDT shares.

According to analysts, Medtronic's stock has a predicted upside of 9.21% based on their 12-month stock forecasts.

Over the previous 90 days, Medtronic's stock had 3 upgrades by analysts.

Analysts like Medtronic less than other "medical" companies. The consensus rating score for Medtronic is 2.61 while the average consensus rating score for "medical" companies is 2.79. Learn more on how MDT compares to other companies.


This page (NYSE:MDT) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners